Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Loegering

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Biological Chemistry|November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergyXue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Louis Letendre, et al.
Haematologica|September 3, 2013
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cellsHusheng Ding, Jennifer S McDonald, Seongseok Yun, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Biological Chemistry|November 6, 2009
Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergyXue Wei Meng, Michael P Heldebrant, Karen S Flatten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Louis Letendre, et al.
Haematologica|September 3, 2013
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cellsHusheng Ding, Jennifer S McDonald, Seongseok Yun, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Pageof 2